Compare MATV & FLGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MATV | FLGT |
|---|---|---|
| Founded | 1995 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Paper | Medical Specialities |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 644.7M | 697.3M |
| IPO Year | 1995 | 2016 |
| Metric | MATV | FLGT |
|---|---|---|
| Price | $12.66 | $26.69 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 3 |
| Target Price | $10.00 | ★ $28.33 |
| AVG Volume (30 Days) | ★ 301.9K | 272.3K |
| Earning Date | 11-05-2025 | 11-07-2025 |
| Dividend Yield | ★ 3.17% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,982,500,000.00 | $315,549,000.00 |
| Revenue This Year | $2.62 | $16.84 |
| Revenue Next Year | $2.26 | $9.74 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 0.39 | ★ 13.61 |
| 52 Week Low | $4.34 | $14.57 |
| 52 Week High | $13.57 | $31.04 |
| Indicator | MATV | FLGT |
|---|---|---|
| Relative Strength Index (RSI) | 55.41 | 43.54 |
| Support Level | $11.78 | $26.69 |
| Resistance Level | $12.26 | $31.04 |
| Average True Range (ATR) | 0.44 | 0.74 |
| MACD | 0.00 | -0.46 |
| Stochastic Oscillator | 54.86 | 2.83 |
Mativ Holdings Inc is a leader in specialty materials, solving its customers' complex challenges by engineering bold, inventive solutions that connect, protect, and purify the world. The company operates in two segments namely Filtration & advanced Materials focused on filtration media and components, developed films, coating and converting solutions, and extruded mesh products, and (2) Sustainable & Adhesive Solutions (SAS), focused on tapes, labels, liners, specialty paper, packaging and healthcare solutions.
Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in laboratory services business and a therapeutic development business. The laboratory services business which generates key revenue includes, technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue; and Foreign.